François Meyer joins FIPRA as Special Advisor on Health Technology Assessment

We are delighted to welcome François Meyer as a Special Advisor on Health Technology Assessment (HTA). François has held high-level positions at the French National Authority for Health (HAS)  and brings extensive experience into the FIPRA team on HTA .

François joined the management team of HAS in 2005, leading the setup of the HTA Division across key areas like pharmaceuticals, medical devices, interventional and diagnostic procedures, and public health programs. He expanded HAS's role in economic analysis within France's HTA field. He  then focused on international cooperation, serving on the HTAi Board for two terms, coordinating EUnetHTA activities, and representing HAS in projects including Post Launch Evidence Generation with HTA-EMA cooperation.

"I'm pleased to join FIPRA as Special Advisor for HTA. My experience at the HAS in FIPRA-led dialogues was marked by their transparent and professional policy development,  delivering trusted and meaningful public-private collaboration. I'm eager to contribute to addressing shared challenges, bringing stakeholders together to respond to the challenges across the therapy lifecycle”.

François Meyer, Special Advisor on Health Technology Assessment

Before joining HAS, François held management roles at the French Medicines Agency (now ANSM). He was active at the EMA, serving on the Committee for Orphan Medicinal Products. François holds an MD in Internal Medicine and Endocrinology from the University of Montpellier, practiced at teaching hospitals there for years, and later worked at a prominent pharmaceutical company.

Laura Batchelor, Head of the Healthcare and Life Sciences Practice welcomes Francois to the team “ We are excited to have François on board, and look forward  to  delivering a positive impact  for stakeholders  across HTA and healthcare policies.”

Let's talk!  
Make your
policy impact
with FIPRA